rEECur
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
International randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Recruitment completed
Summary
A comparison of four widely used chemotherapy regimens for the treatment of Ewing sarcoma, a type of bone cancer, to see which is most effective and/or has the fewest side effects.
Main inclusion criteria
- Histologically confirmed Ewing sarcoma.
- Disease recurrence or progression after completion of first line treatment OR
- Refractory disease, defined by progression during first line treatment or within 12 weeks of its completion. Disease progression will be based on Response Evaluation Criteria In Solid Tumors (RECIST). The appearance of new bone lesions on bone scan will require confirmation with cross-sectional imaging.
- Soft tissue disease component evaluable by cross-sectional imaging. Patients with bone disease without a measurable soft tissue component or bone marrow disease only will be eligible for the study but will not contribute to the phase II primary outcome measure.
- Age ≥4 years and <50 years.
- Patient assessed as medically fit to receive cytotoxic chemotherapy.
Sponsor
University of Birmingham